Literature DB >> 8432886

Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.

J E Howarth1, H M Waters, D Shanks, K Hyde, J A Yin, C G Geary, E Anastassiades, D Howarth, R Gokal.   

Abstract

AIMS: To determine the effect of concomitant azathioprine treatment on the response of patients with renal failure to treatment with subcutaneous recombinant human erythropoietin (r-HuEPO).
METHODS: Two groups of patients with renal failure not receiving haemodialysis were studied. One comprised seven patients receiving erythropoietin alone, the second consisted of nine patients who were also treated with azathioprine. The haematological changes were monitored, and the functional erythropoietic response was studied by two different ferrokinetic models. One analysed the initial, the other the extended plasma iron clearance. Studies were performed before r-HuEPO treatment on all 16 patients, and repeated on 11 of these when the target haemoglobin (10-11 g/dl) was achieved and stabilised. Total erythropoiesis was determined using both techniques. Analysis of the extended plasma iron clearance also permitted calculation of both effective and ineffective erythroid activity.
RESULTS: The haematological response to r-HuEPO was the same for both patient groups. Measurement of total erythropoiesis by both ferrokinetic methods showed good correlation. For those receiving long term azathioprine, the percentage ineffective erythropoiesis was high compared with that of the other patients, and remained so for as long as they continued with azathioprine. For those uncomplicated by azathioprine treatment, r-HuEPO increased levels of both effective and ineffective erythropoiesis by the same degree. A substantial reduction in ineffective erythropoiesis was shown only by those patients who either discontinued or reduced their azathioprine once they started r-HuEPO treatment.
CONCLUSIONS: Azathioprine increases ineffective erythropoiesis. In this study, the r-HuEPO dose was sufficient to overcome this effect and promoted effective erythropoiesis so that the anaemia lessened. Measurement of total erythropoiesis provided limited information on the functional changes involved, differentiation of effective from ineffective erythropoiesis being necessary to define the changes after azathioprine reduction or withdrawal.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432886      PMCID: PMC501111          DOI: 10.1136/jcp.46.1.41

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  21 in total

1.  Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe.

Authors:  C Ricketts; A Jacobs; I Cavill
Journal:  Br J Haematol       Date:  1975-09       Impact factor: 6.998

2.  Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients.

Authors:  I C Macdougall; I Cavill; M E Davies; R D Hutton; G A Coles; J D Williams
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

3.  Subcutaneous erythropoietin and peritoneal dialysis.

Authors:  J M Stevens; C A Strong; D O Oliver; C G Winearls; P M Cotes
Journal:  Lancet       Date:  1989-06-17       Impact factor: 79.321

4.  Standard techniques for the measurement of red-cell and plasma volume. A report by the International Committee for Standardization in Hematology (ICSH): Panel on Diagnostic Applications of Radioisotopes in Haematology.

Authors: 
Journal:  Br J Haematol       Date:  1973-12       Impact factor: 6.998

5.  Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure.

Authors:  S F Wallner; R M Vautrin
Journal:  J Lab Clin Med       Date:  1981-02

6.  Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency.

Authors:  R J McGonigle; J D Wallin; R K Shadduck; J W Fisher
Journal:  Kidney Int       Date:  1984-02       Impact factor: 10.612

7.  Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera.

Authors:  C J Eaves; A C Eaves
Journal:  Blood       Date:  1978-12       Impact factor: 22.113

8.  Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.

Authors:  J W Eschbach; M R Kelly; N R Haley; R I Abels; J W Adamson
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

9.  Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.

Authors:  R T Hughes; P M Cotes; M J Pippard; J M Stevens; D O Oliver; C G Winearls; J P Royston
Journal:  Br J Haematol       Date:  1990-06       Impact factor: 6.998

10.  Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.

Authors:  J R Boelaert; M L Schurgers; E G Matthys; F M Belpaire; R F Daneels; M J De Cre; M G Bogaert
Journal:  Perit Dial Int       Date:  1989       Impact factor: 1.756

View more
  1 in total

Review 1.  Hematologic abnormalities following renal transplantation.

Authors:  Mark A Marinella
Journal:  Int Urol Nephrol       Date:  2009-03-20       Impact factor: 2.266

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.